Directorate Change

GlaxoSmithKline PLC
22 December 2005

Issued -   Thursday 22 December 2005, London, UK  / London Stock Exchange
announcement





                         GlaxoSmithKline plc Announces

                       Changes to the Board of Directors



GlaxoSmithKline plc (GSK) announces that two new Non-Executive Directors are to
join the Board of the Company with effect from 1st January 2006 and that Dr Lucy
Shapiro will be retiring as a Non-Executive Director at the Company's Annual
General Meeting on 17th May 2006.  The two new Non-Executives are:



Dr Ralph Horwitz,   Dean, School of Medicine and Vice President
                    of Medical Affairs at Case Western Reserve University,
                    Cleveland, Ohio and Director of Case Research Institute.



Mr Tom De Swaan,    Currently, Chief Financial Officer and member
                    of the Management Board of ABN AMRO.



In commenting on the retirement of Dr Shapiro and the appointment of Dr Horwitz,
Sir Christopher Gent, Chairman of GSK, said:



"During the last nine years Lucy has provided the Board with invaluable advice
and support for which I and my Board colleagues are immensely grateful.



I am delighted that Ralph has agreed to join the Board. In addition to
fulfilling his usual responsibilities as a Non-Executive Director, he will spend
time within our research and development organisation and, with his experience,
will provide valuable insights to scientific and clinical developments outside
GSK."



On his appointment to GSK, Mr De Swaan will join the Audit Committee and will
succeed Dr Ronaldo Schmitz as its Chairman in September 2006.  Commenting on Mr
De Swaan's appointment, Sir Christopher Gent said:



 "I am very glad that Tom, who has had a long and distinguished career in
international banking, has agreed to join the Board and take over from Ronaldo
as Chairman of the Audit Committee. This is a challenging and demanding role
that Ronaldo has undertaken with great skill and I am delighted that he has also
agreed to remain on the Board for a further term of three years."


Biographical details of the Directors mentioned above are given below together
with a table showing the membership of the Board and its committees with effect
from 1st January 2006.



Simon Bicknell

Company Secretary



22 December 2005





Notes

1.         The Board has determined that Dr Horwitz and Mr De Swaan are each
independent in accordance with the Combined Code on Corporate Governance.  The
Board also agreed that Dr Schmitz remains independent in character and judgement
and that it would be appropriate for him to continue to be considered an
independent Non-Executive Director following the AGM in 2006, when he will have
completed nine years service as a Non-Executive Director.

2.         In accordance with the Combined Code, the Board has determined that
Mr De Swaan has recent and relevant financial experience.  The Board has also
agreed that Mr De Swaan has the appropriate qualifications and background to be
an Audit Committee Financial Expert in accordance with the requirements of
Sarbanes-Oxley Act 2002.



Biographical Details

Dr Ralph Horwitz

Age 58.  Dr Horwitz was appointed vice president for medical affairs and dean of
the School of Medicine at Case Western Reserve University and director of the
Case Research Institute on April 1, 2003.

Prior to joining Case, Ralph Horwitz was Harold H. Hines Professor of Medicine
and Epidemiology at the Yale University School of Medicine and chairman of the
Department of Internal Medicine, co-director of the Robert Wood Johnson Clinical
Scholars Program, and chief of the Beeson Medical Service at Yale-New Haven
Hospital.  Dr. Horwitz is internationally known for his pioneering research that
helped to establish the field of clinical investigation and outcomes research;
for his distinguished leadership in reinvigorating the Department of Medicine at
Yale and for his innovative programs in the education of physicians and the
training of physician scientists.

Among his recent honours, he is the recipient of the Pennsylvania State
University Distinguished Alumnus Award (2005) and the Robert J. Glaser Research
Award (2005).  He is an elected member of the American Society of Clinical
Investigation, American Epidemiology Society, the Institute of Medicine of the
National Academy of Sciences, and the Association of American Physicians (AAP).
He is a former chair of the American Board of Internal Medicine and is currently
a member of the Council of the AAP.





Mr Tom De Swaan

Age 59.  Mr. De Swaan holds a Master degree in Economics and is a Member of the
Managing Board and CFO of ABN AMRO. He will step down as CFO on 1 January 2006
and retire from the Board of ABN AMRO from 1 May 2006.



Prior to his tenure with ABN AMRO he was from 1986 - 1998 a Member of the
Governing Board of the Dutch Central Bank and in that capacity Chairman of the
Basel Committee on Banking Supervision.



He is a Non-Executive Director of the Financial Services Authority. He is a
Member of the Board of the Institute of International Finance. He is Chairman of
the Board of the Nederlands Opera and a Member of the Board of Royal
Concertgebouw Orchestra.



Dr Ronaldo Schmitz

Age 67.  Dr Schmitz is an independent Non-Executive Director of GlaxoSmithKline
plc.  He was a Non-Executive Director of Glaxo Wellcome plc from 1st January
1997 until the completion of the merger with SmithKline Beecham plc in December
2000. He is a Non-Executive Director of Legal & General Group plc and a member
of the Board of Directors of Rohm and Haas Company and Cabot Corporation.



Dr Lucy Shapiro

Age 65. Dr Shapiro is a Non-Executive Director of GlaxoSmithKline plc. She was
formerly a
Non-Executive Director of SmithKline Beecham plc. She is Ludwig Professor of
Cancer Research in the Department of Developmental Biology and Director of the
Beckman Center for Molecular and Genetic Medicine at the Stanford University
School of Medicine and a Non-Executive Director of Anacor Pharmaceuticals, Inc.
She holds a PhD in molecular biology from Albert Einstein College of Medicine.






                         Board and Committee Membership

                       with effect from 1st January 2006.





Sir Christopher Gent                   Chairman

Sir Ian Prosser                        Senior Independent Non-Executive Director



Dr J-P Garnier                         Chief Executive Officer

Mr J S Heslop                          Chief Financial Officer

Dr Tachi Yamada                        Executive Director, Chairman, Research &
                                       Development



Mr H Lawrence Culp                     Independent Non-Executive Director

Sir Crispin Davis                      Independent Non-Executive Director

Dr Ralph Horwitz                       Independent Non-Executive Director

Sir Deryck Maughan                     Independent Non-Executive Director

Dr Ronaldo Schmitz                     Independent Non-Executive Director

Dr Lucy Shapiro                        Non-Executive Director

Mr Tom De Swaan                        Independent Non Executive Director

Sir Robert Wilson                      Independent Non-Executive Director








         Board Committee                    Committee Chairman                        Members


Audit                              Dr Ronaldo Schmitz*                   Sir Deryck Maughan

                                                                         Sir Ian Prosser

                                                                         Mr Tom De Swaan*

                                                                         Sir Robert Wilson


Remuneration                       Sir Robert Wilson                     Mr H Lawrence Culp

                                                                         Sir Crispin Davis

                                                                         Dr Ronaldo Schmitz


Nominations                        Sir Christopher Gent                  Sir Ian Prosser

                                                                         Dr Ronaldo Schmitz

Corporate Responsibility           Sir Christopher Gent                  Sir Ian Prosser

                                                                         Dr Lucy Shapiro





* Mr De Swaan will succeed Dr Schmitz as Chairman of the Audit Committee in
September 2006.






Enquiries:

UK Media enquiries:                                    Philip Thomson          [phone]
                                                       David Mawdsley          [phone]
                                                       Chris Hunter-Ward       [phone]

US Media enquiries:                                    Nancy Pekarek           [phone]
                                                       Mary Anne Rhyne         [phone]
                                                       Patricia Seif           (215)  751 7709

European Analyst/Investor enquiries:                   Duncan Learmouth        [phone]
                                                       Anita Kidgell           [phone]
                                                       Jen Hill                [phone]

US Analyst/ Investor enquiries:                        Frank Murdolo           [phone]
                                                       Tom Curry               [phone]








                      This information is provided by RNS
            The company news service from the London Stock Exchange